论文部分内容阅读
(续上期)5.2波塞瑞韦胶囊由Merck公司开发,2011年5月13日获得FDA批准,用于联合聚乙二醇化α-干扰素(peginterferon alfa)和利巴韦林(ribavirin)方案治疗≥18岁成人无既往治疗史或已经既往α-干扰素(interferon alfa)和利巴韦林方案治疗失败的呈代偿性肝病、包括已伴肝硬化的基因型为1的慢性丙型肝炎(CHC)患者。
(Continued) 5.2 Posaconline Capsules Developed by Merck and FDA Approved May 13, 2011 for Combination Peginterferon alfa and Ribavirin Regimens Adults 18 and older who have no prior history of treatment or who have had previous failure to respond to interferon alfa and ribavirin regimens include chronic hepatitis C with cirrhosis genotype 1 ( CHC) patients.